ZNF3 Antibody

What is ZNF3 and what are its key structural features?

ZNF3 (Zinc Finger Protein 3) is a transcription factor belonging to the krueppel C2H2-type zinc-finger protein family. The canonical human ZNF3 protein contains 446 amino acids with a molecular weight of approximately 51 kDa. Its key structural features include:

• 8 C2H2-type zinc finger domains that facilitate DNA binding

• 1 KRAB (Krüppel-associated box) domain that typically functions as a transcriptional repressor

• Nuclear localization due to its function as a transcription factor

ZNF3 is also known by alternative names including Zinc finger protein KOX25, Zinc finger protein HF.12, and Zinc finger protein HZF3.1. The protein is involved in cell differentiation and proliferation processes, with emerging evidence suggesting roles in cancer development .

What applications are ZNF3 antibodies commonly used for?

ZNF3 antibodies are utilized across multiple experimental applications in research settings. The most common applications include:

For optimal results, validation experiments should be performed to determine the ideal dilution for each specific application and sample type .

How should I design experiments to validate ZNF3 antibody specificity?

Validating antibody specificity is crucial for generating reliable data. A comprehensive validation approach for ZNF3 antibodies should include:

• Positive and negative controls:

  • Positive: Cell lines known to express ZNF3 (e.g., A2780 cells, mouse ovary and testis tissues)

  • Negative: ZNF3 knockout/knockdown cells or low-expressing cell lines

• Multiple detection methods:

  • Western blot analysis showing a single band at the expected molecular weight (47-51 kDa)

  • Immunoprecipitation followed by mass spectrometry

  • Immunohistochemistry with appropriate controls

• Blocking peptide competition:

  • Pre-incubation of the antibody with the immunizing peptide should abolish specific signals

• Cross-reactivity assessment:

  • Testing reactivity against related zinc finger proteins to ensure specificity

  • Confirming minimal cross-reactivity with human, mouse, and rat orthologs (sequence identity comparisons: mouse - 77%, rat - 78%)

When evaluating Western blot results, verification should show a clean band at the expected 47-51 kDa range with minimal background .

What are the critical parameters for optimizing ZNF3 antibody performance in Western blot applications?

Optimizing Western blot protocols for ZNF3 detection requires careful attention to several parameters:

• Sample preparation:

  • Complete lysis with appropriate buffers containing protease inhibitors

  • Fresh sample preparation or proper storage at -80°C

  • Appropriate protein quantification and loading (typically 20-50 μg total protein)

• Blocking conditions:

  • 5% non-fat dry milk or BSA in TBST (application-dependent)

  • Blocking time: 1-2 hours at room temperature or overnight at 4°C

• Antibody dilution optimization:

  • Primary antibody: Start with manufacturer's recommendation (typically 1:500-1:2000)

  • Secondary antibody: Usually 1:5000-1:10000

• Incubation conditions:

  • Primary antibody: Overnight at 4°C or 2 hours at room temperature

  • Secondary antibody: 1-2 hours at room temperature

• Washing stringency:

  • Multiple TBST washes (3-5 times, 5-10 minutes each)

  • Consider increased washing for high background issues

• Detection system selection:

  • Enhanced chemiluminescence for high sensitivity

  • Fluorescent detection for quantitative analysis

Follow antibody-specific protocols when available, as some ZNF3 antibodies may require specialized conditions for optimal performance .

How can ZNF3 antibodies be effectively used to study its role in cancer progression?

Recent research has implicated ZNF3 in cancer development, particularly in colorectal cancer (CRC). To effectively study its role:

• Expression analysis across cancer stages:

  • Use IHC to quantify ZNF3 expression in tumor microarrays

  • Apply scoring systems for staining intensity (0-3 points) and percentage of positive cells (1-4 points)

  • Correlate expression with clinical parameters and outcomes

• Functional studies using genetic manipulation:

  • Generate stable ZNF3 knockdown or overexpression cell lines

  • Use lentiviral shRNA constructs (e.g., sequences like 5′-GGAACCTCAGGCCCTGCTTGA-3′) or overexpression vectors

  • Validate knockdown/overexpression by Western blot with ZNF3 antibodies

• Downstream signaling analysis:

  • Investigate ZNF3's effect on EMT-related markers (TWIST, MMP1, Vimentin)

  • Perform RNA-seq and ChIP-seq to identify transcriptional targets

  • Validate findings with ZNF3 antibodies in Western blot, ChIP, and IP applications

• In vivo model validation:

  • Establish xenograft models with ZNF3-modulated cells

  • Analyze tumor growth, invasion, and metastasis

  • Use ZNF3 antibodies for ex vivo analysis of tumor samples

Research has shown that ZNF3 is upregulated in colorectal cancer tissues compared to normal tissues and is associated with patient age (higher expression in patients older than 55 years). ZNF3 knockdown suppresses CRC cell proliferation, migration, and invasion, while promoting G0/G1 phase cell cycle arrest .

What are effective strategies for resolving common issues with ZNF3 antibody specificity in immunohistochemistry?

Immunohistochemistry with ZNF3 antibodies can present several challenges that require methodical troubleshooting:

• Background reduction strategies:

  • Optimize antibody concentration through titration experiments

  • Extend blocking time or increase blocking agent concentration

  • Include additional blocking steps with normal serum from secondary antibody species

  • Consider biotin/avidin blocking for biotin-based detection systems

• Epitope retrieval optimization:

  • Compare heat-induced epitope retrieval methods (citrate buffer pH 6.0, EDTA buffer pH 9.0)

  • Test different retrieval times (10-30 minutes)

  • Evaluate enzyme-based retrieval alternatives for sensitive tissues

• Signal enhancement with minimal background:

  • Implement tyramide signal amplification (TSA) for low-abundance proteins

  • Use polymer-based detection systems instead of ABC methods

  • Consider automated staining platforms for consistency

• Validation through multiple approaches:

  • Confirm localization patterns with immunofluorescence

  • Parallel analysis with RNA-scope or in situ hybridization

  • Use multiple antibodies targeting different ZNF3 epitopes

For ZNF3, nuclear staining is expected based on its function as a transcription factor. Validation should include prostate tissue samples, which have shown reliable ZNF3 expression patterns in previous studies .

How can researchers effectively use ZNF3 antibodies in chromatin immunoprecipitation (ChIP) experiments to identify genomic binding sites?

While standard ChIP protocols require optimization for specific proteins, the following considerations are particularly important for ZNF3 ChIP experiments:

• Crosslinking optimization:

  • Test different formaldehyde concentrations (0.75-1.5%)

  • Evaluate dual crosslinking with DSG followed by formaldehyde for improved zinc finger protein fixation

  • Optimize crosslinking times (10-20 minutes) to balance efficiency and chromatin quality

• Chromatin fragmentation:

  • Sonication parameters should be carefully optimized to achieve 200-500 bp fragments

  • Monitor fragmentation by agarose gel electrophoresis

  • Consider enzymatic digestion alternatives for sensitive samples

• Immunoprecipitation conditions:

  • Use higher antibody amounts than typical ChIP (5-10 μg per reaction)

  • Include longer incubation times (overnight at 4°C with gentle rotation)

  • Consider pre-clearing lysates with protein A/G beads to reduce background

• Controls and validation:

  • Include IgG negative controls from the same species as the ZNF3 antibody

  • Use positive controls targeting known chromatin marks (H3K4me3)

  • Validate ChIP-seq peaks with targeted ChIP-qPCR

  • Confirm ZNF3 binding motifs through bioinformatic analysis

• Data analysis considerations:

  • Look for enrichment of C2H2 zinc finger binding motifs

  • Compare to published transcription factor databases

  • Integrate with RNA-seq data to correlate binding with gene expression

Since ZNF3 belongs to the krueppel C2H2-type zinc-finger protein family, ChIP-seq analysis should focus on identifying consensus DNA binding motifs characteristic of this family .

What methodological approaches are recommended when using ZNF3 antibodies to investigate protein-protein interactions?

Investigating ZNF3 protein interactions requires careful experimental design:

• Co-immunoprecipitation (Co-IP) optimization:

  • Nuclear extraction protocols are essential since ZNF3 is primarily nuclear

  • Use gentle lysis buffers containing low concentrations of detergents (0.1-0.5% NP-40)

  • Include DNase treatment to distinguish DNA-mediated versus direct protein interactions

  • Test both N- and C-terminal directed ZNF3 antibodies to avoid epitope masking by interaction partners

• Proximity ligation assay (PLA) approach:

  • Combines the specificity of antibody recognition with the sensitivity of PCR

  • Requires validated ZNF3 antibody pairs from different species or isotypes

  • Provides spatial information about interactions in cellular context

  • Optimal for detecting transient or weak interactions

• Bimolecular fluorescence complementation (BiFC):

  • Complement with recombinant approaches when antibody-based methods are challenging

  • Validate interactions identified through antibody-based methods

  • Control for protein overexpression artifacts

• Mass spectrometry validation:

  • IP-MS using ZNF3 antibodies followed by mass spectrometry

  • Include stringent controls (IgG pull-downs, reverse IPs)

  • Implement SILAC or TMT labeling for quantitative interaction analysis

Based on studies of related zinc finger proteins, focus on potential interactions with transcriptional co-regulators, chromatin modifiers, and components of the transcriptional machinery .

What quality control measures should be implemented to ensure reproducible results with ZNF3 antibodies across different experimental batches?

Ensuring experimental reproducibility with ZNF3 antibodies requires systematic quality control:

• Antibody validation with each new lot:

  • Western blot analysis with positive control samples

  • Comparison of staining patterns between lots

  • Concentration adjustments based on lot-specific activity

• Sample preparation standardization:

  • Consistent cell culture conditions (passage number, confluence)

  • Standardized tissue collection and processing protocols

  • Uniform fixation times for IHC/ICC applications

• Protocol documentation and standardization:

  • Detailed SOP development with critical parameters clearly defined

  • Temperature and timing control for all incubation steps

  • Consistent reagent sources and preparation methods

• Internal controls implementation:

  • Include standard positive samples in each experiment

  • Use reference protein loading controls for Western blots

  • Incorporate tissue microarrays with known ZNF3 expression patterns for IHC

• Data acquisition standardization:

  • Fixed exposure times for Western blot imaging

  • Consistent microscope settings for immunofluorescence

  • Blinded analysis of staining patterns and intensities

Multiple ZNF3 antibodies from different vendors have been validated in published research, with optimal dilutions ranging from 1:500-1:2000 for Western blot applications .

How should researchers interpret conflicting results when different ZNF3 antibodies produce varying patterns in the same experimental system?

When encountering discrepancies between different ZNF3 antibodies:

• Epitope mapping analysis:

  • Compare the immunogens used to generate each antibody

  • Antibodies targeting different domains may reveal different aspects of protein function

  • Epitope accessibility can vary depending on protein conformation or interactions

• Isoform specificity evaluation:

  • Determine if antibodies recognize different ZNF3 isoforms

  • Compare results with transcript analysis (RT-PCR, RNA-seq)

  • Consider alternative splicing events that might affect epitope presence

• Post-translational modification interference:

  • Evaluate if modifications (phosphorylation, ubiquitination) mask epitopes

  • Use phosphatase treatment to determine if phosphorylation affects antibody binding

  • Compare results with mass spectrometry analysis of modifications

• Methodological validation through orthogonal approaches:

  • Confirm protein expression using genetic approaches (siRNA knockdown)

  • Employ epitope-tagged ZNF3 constructs to validate antibody specificity

  • Use multiple detection methods to corroborate findings

• Literature comparison and community standards:

  • Review published literature for validated ZNF3 antibodies

  • Contact authors of conflicting publications for technical advice

  • Consider multi-laboratory validation for critical findings

Different reactivity patterns have been observed between antibodies that target different regions of ZNF3, with some showing stronger nuclear staining and others detecting both nuclear and cytoplasmic signals. These variations may reflect biologically relevant differences in protein localization, modification, or conformation states .

What are the recommended methodological approaches for using ZNF3 antibodies in single-cell analysis techniques?

As single-cell technologies advance, applying ZNF3 antibodies in this context requires specialized approaches:

• Single-cell Western blot adaptations:

  • Optimize cell lysis conditions for minimal protein loss

  • Increase antibody concentrations (typically 2-5 fold higher than standard Western blots)

  • Extend incubation times to compensate for reduced protein amounts

  • Implement signal amplification systems for enhanced sensitivity

• Mass cytometry (CyTOF) applications:

  • Metal-conjugate ZNF3 antibodies for CyTOF analysis

  • Validate metal-conjugated antibodies against unconjugated versions

  • Include proper isotype controls and titration experiments

  • Combine with other markers for comprehensive cellular profiling

• Imaging mass cytometry optimization:

  • Test different tissue preparation protocols to maintain epitope integrity

  • Optimize antibody concentration through titration on control tissues

  • Implement multiplexed panels with validated markers for cellular context

  • Apply appropriate segmentation algorithms for single-cell analysis

• Single-cell immunofluorescence considerations:

  • Microfluidic capture systems for consistent cell handling

  • High-sensitivity cameras and appropriate exposure settings

  • Autofluorescence correction and background subtraction

  • Quantitative image analysis with single-cell segmentation

These advanced applications require rigorous validation using cells with known ZNF3 expression levels as positive controls (such as A2780 cells) and appropriate negative controls .

How can ZNF3 antibodies be integrated into multiparametric analysis to understand its role in transcriptional networks?

Understanding ZNF3's role in broader transcriptional networks requires integrated multiparametric approaches:

• Multiplexed immunofluorescence strategy:

  • Select compatible antibody pairs for co-localization studies

  • Use spectral unmixing to resolve overlapping fluorophores

  • Implement sequential staining protocols for challenging combinations

  • Include transcription factors that potentially interact with ZNF3

• Combined ChIP-seq and proteomics approaches:

  • Perform sequential ChIP (Re-ChIP) to identify co-binding patterns

  • Integrate ChIP-seq data with proximity labeling proteomics

  • Validate interactions through co-immunoprecipitation with ZNF3 antibodies

  • Apply network analysis to identify functional modules

• Spatial transcriptomics integration:

  • Combine ZNF3 antibody staining with spatial transcriptomics

  • Correlate protein localization with target gene expression patterns

  • Implement computational approaches to infer regulatory relationships

  • Validate findings through targeted perturbation experiments

• Systems biology data integration:

  • Develop mathematical models of ZNF3-containing regulatory networks

  • Incorporate ChIP-seq, RNA-seq, and protein interaction data

  • Predict and experimentally validate network perturbation effects

  • Apply machine learning approaches to identify contextual dependencies

Research suggests ZNF3 may regulate genes involved in cell cycle progression, invasion, and EMT pathways. ZNF3 knockdown studies have demonstrated reduced expression of EMT-related markers like TWIST and MMP1, suggesting involvement in cancer progression pathways that warrant further investigation through these integrated approaches .